# Xeris Biopharma Holdings, Inc. (XERS) — capital_raise/private_placement [announced]
Source: SEC API (secapi.ai) · situation sit_33e0aa02b8bcb4e43def · retrieved 2026-08-11T15:49:17.818Z

## Overview
Xeris Biopharma Holdings, Inc. is a pharmaceutical company engaged in the development and commercialization of pharmaceutical preparations.

On July 15, 2026, Xeris Biopharma Holdings, Inc. completed privately negotiated exchange transactions with holders of its 8.00% Convertible Senior Notes due 2028. The Exchanging Noteholders exchanged approximately $23 million in aggregate principal amount of the 2028 Notes for approximately 5.0 million shares of common stock and approximately $23 million in cash. The Company funded the cash portion with liquidity on-hand, and the exchanged 2028 Notes were immediately cancelled. Separately, a holder of $10.5 million in principal amount of the 2028 Notes elected to convert their notes into approximately 3.6 million shares of common stock. Following both transactions, no 2028 Notes remain outstanding.

## Terms
- Counterparty: Holders of 8.00% Convertible Senior Notes due 2028 · Consideration: mixed

## Key dates
- Announced 2026-07-17

## Timeline
- 2026-07-17 · 8-K (0001867096-26-000055): 8-K - Xeris Biopharma Holdings, Inc. — *Xeris Biopharma Holdings, Inc. is a pharmaceutical company engaged in the development and commercialization of pharmaceutical preparations.* On July 15, 2026, Xeris Biopharma Holdings, Inc. completed privately negotiated exchange transactions with holders of its 8.00% Convertible Senior Notes due 2028. The Exchanging Noteholders exchanged approximately $23 million in aggregate principal amount of the 2028 Notes for approximately 5.0 million shares of common stock and approximately $23 million in cash. The Company funded the cash portion with liquidity on-hand, and the exchanged 2028 Notes were immediately cancelled. Separately, a holder of $10.5 million in principal amount of the 2028 Notes elected to convert their notes into approximately 3.6 million shares of common stock. Following both transactions, no 2028 Notes remain outstanding.
  https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000055.txt

## Citations
- 0001867096-26-000055 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000186709626000055